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comprising100 US hospitals, we identified admissions (1/1/2007 - 6/30/2010) with
cSSSI who received initial antibiotic therapy with vancomycin or daptomycin. A
propensity score model was estimated, using demographics, comorbidities, labo-
ratory values, and receipt of vancomycin30 days prior to hospitalization. Vanco-
mycin patients were matched 1:1 to daptomycin patients in stepwise fashion to
minimize the difference in propensity scores for each matched pair (i.e., “greedy”
matching). RESULTS: We identified 347 patients who received daptomycin and
8963 patients who received vancomycin as initial antibiotic therapy for cSSSI. Four
hospitals contributed 54% of daptomycin patients, but only 17% of vancomycin
patients. Daptomycin and vancomycin patients differed significantly in a number
of respects. Only 47.6% of daptomycin patients could be matched to vancomycin
patients (i.e., most patients had nonoverlapping propensity scores). Unmatched
daptomycin patients were older than those in the matched subset (mean age:
57.3yrs vs. 52.3yrs); they alsoweremore likely to have chronic/ulcerative infections
(23% vs. 10%), comorbidities (e.g., diabetes [19% vs. 0%], malnutrition [4% vs. 0%],
alcohol/drug abuse [11% vs. 1%]), and to have been hospitalized previously (63% vs.
39%) (all p0.01). CONCLUSIONS:While PSM is often used to control for selection
bias, the problem of nonoverlapping propensity score distributions is often over-
looked and can adversely impact generalizability. Use of PSM to control for selec-
tion bias in “real-world” comparisons of initial antibiotic therapy for infectious
diseases may be limited; alternate study designs may be needed.
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OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC
and the allocation of $1.1 billion for comparative effectiveness research by the
United States, are strong indicators of trends in pricing and reimbursement that
are likely to be observed in the future. To gain an additional insight into these
trends,we analyzed the cost effectiveness studies for the top twenty highest selling
drugs ($90-100B worldwide sales) METHODS: The Top 20 drugs were selected
based on their worldwide sales. For this analysis, we segmented these drugs into
categories as primary care, specialty, small molecules, biologics, therapy areas and
availability of generic alternatives. We analyzed the cost effectiveness studies that
were published in peer-reviewed journals. Search was conducted using generic
names of the drugs and the phrase cost effectiveness in abstract of the published
study. RESULTS:During 2005-2010, the number of published studies on cost effec-
tiveness have increased by more than 30%. There is a large variability in CERs for
same drugs for different indications, in some cases also varying by biomarkers.
Primary care drugs had lower and less variable CERs than specialty drugs. Varia-
tions also exist in methodology used by different groups in modeling cost effec-
tiveness, especially for time horizon and comparator. Majority of primary care
drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate
cost effectiveness. CONCLUSIONS: This analysis shows the range, variability and
methods used for calculation of ICER values for these high budget impact drugs and
provides lessons for executives and policy makers.
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OBJECTIVES:Monotherapy with a mood stabilizer (MS) or second generation anti-
psychotic (SGA) is recommended as the first-line treatment for pediatric bipolar
disorder (PBD). The existing evidence regarding the relative effectiveness of MSs
and SGAs for PBD is predominantly based on short-term studies and does not
adequately address long-term effectiveness. This study compared adherence, per-
sistence, and bipolar-related hospitalization of these treatments during a one-year
observation period. METHODS: The 2003-2007 Medicaid Analytic eXtract data for
four states were used. Bipolar children and adolescents (aged 6-18 years) initiating
treatmentwith SGA orMSmonotherapywere identified. Adherencewasmeasured
using medication possession ratio (MPR) and persistence was measured as time to
medication discontinuation and time to augmentation. Survival Analyseswas con-
ducted to compare time to first bipolar-related hospitalization, time to discontin-
uation and time to augmentation between MS and SGA recipients during a one-
year period after treatment initiation. Heckman’s Two-Step Selection Correction
was used in all survival models to control for treatment selection bias. RESULTS: A
total of 8424 PBD patients were identified. Prescription of SGAs (64.08%) was pre-
dominantly higher than that of MSs (35.92%). The most frequently prescribed SGA
was risperidone, followed by quetiapine and aripiprazole. Divalproex sodium and
oxcarbazepine were most frequently prescribed among MSs. 55% of the patients
initiated on either of the therapeutic category were fully adherent. After correcting
for selection bias, there was no statistically significant difference in the MPR, time
to discontinuation and time to hospitalization between the two study groups. Pa-
tients initiating on SGAs took a longer time to augment (Hazard Ratio: 0.71; 95%CI:
0.57-0.88) with MSs as compared to those who initiated with MSs. CONCLUSIONS:
Although SGAs were prescribed predominantly more than MSs, the two therapeu-
tic classes were comparable in adherence and preventing bipolar related hospital-
ization. SGAs appeared to be slightly better than MSs in terms of time to augmen-
tation.
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OBJECTIVES: Observational studies are often necessary for assessing the compar-
ative effectiveness of therapeutics in “real-world” settings. The strength of evi-
dence generated by individual studies, however, varies. We describe the develop-
ment of the GRACE Checklist, a tool for rating the quality of observational CER and
assessing whether studies merit consideration for decision making. METHODS: A
checklist was developed based on existing guidelines for the conduct and reporting
of observational studies, including the GRACE Principles, and existing scales for the
inclusion of observational studies in systematic reviews. An external advisory
board reviewed the checklist content and scoring options; majority opinion of the
advisors was used to refine the question items and scoring. The construct validity
of the checklist was measured using two rounds of testing where over 100 volun-
teer testers rated articles, to determine if the checklist can distinguish studies of
known quality. Articles of “known quality” were first extracted from systematic
reviews and then, in the second round, were based on reviews of observational CER
studies by recognized experts. RESULTS: Two domains, internal validity and ap-
plicability, were identified for inclusion with a total of 15 questions. Results and
proposed scoring algorithms will be presented for a categorical assessment of
study quality to determine if studies are 1) of sufficient quality for decision support;
2) sufficiently flawed to make interpretation unreliable; or 3) require additional
consideration. First round testing results showed that subsets of item responses
could yield positive predictive values for identifying high quality studies as high as
0.86, and negative predictive values as high as 0.91. CONCLUSIONS: A validated
checklist to assess the quality of observational CER can help decision makers rec-
ognize strong evidence without substantial advanced training.
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OBJECTIVES: Soliciting stakeholder input is becoming commonplace in compara-
tive effectiveness research (CER), yet methods for stakeholder engagement in CER
are evolving. Drawing from CMTP and University of Maryland’s experiences across
a variety of NIH, PCORI, and industry-funded activities as well as previously pub-
lished case analyses, we describe a framework for stakeholder engagement in CER
that standardizes approaches for generating meaningful evidence.METHODS:We
conducted a literature search to explore engagement practices in biomedical sci-
ences, social sciences, and business which included the gray literature. The results
were combined with investigator experience to develop a process framework and
corresponding activities for successful stakeholder engagement. RESULTS:We de-
fined five steps- recruitment, preparation, engagement, dissemination, and evalu-
ation- broadly applicable to stakeholder engagement. Recruitment should begin
with clearly defined expectations for involvement and end with balanced repre-
sentation of stakeholders that meet the needs of the project and disclose conflicts
of interest. Preparing stakeholders for participation in CER requires customized
and relevant background materials. Stakeholder engagement by an experienced
facilitator should guide iterative engagement procedures by using deliberative
methods that ensure a fair, competent and trustworthy process. Dissemination
must document the stakeholders’ input and how this information was incorpo-
rated into decision-making or pathways for implementation. Publications should
also acknowledge stakeholder involvement and contributions. Following dissemi-
nation, evaluation provides both researchers and stakeholders an opportunity to
assess the engagement experience and outcomes, which is necessary for refining
practices for future work. CONCLUSIONS: CER is transitioning toward an interac-
tive framework of stakeholder engagement that enhances the traditional research
paradigm. This processmodel provides a standardmethodology to guide this tran-
sition to stakeholder-based research. This process is adaptable acrossmultiple CER
activities including priority-setting, study design, andmethods guidance aswell as
various therapeutic areas. Further research is needed to refine, evaluate, and apply
this model to ongoing CER activities.
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OBJECTIVES:Todetermine differences in processes and outcomes of care in elderly
hypertensive diabetic patients with and without dementia.METHODS: This cross-
sectional study was conducted using the household and medical provider compo-
nent files of Medical Expenditure Panel Survey (MEPS) data from 2003, 2005, 2007
and 2009. Hypertensive diabetic patients 50 years of age were identified using
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